# A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

> **NCT03715829** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 366 (actual)

## Conditions studied

- Active Non-segmental Vitiligo

## Interventions

- **DRUG:** PF-06651600
- **DRUG:** PF-06651600
- **DRUG:** PF-06651600
- **DRUG:** PF-06651600
- **DRUG:** PF-06651600
- **DRUG:** placebo
- **DRUG:** PF06700841
- **DEVICE:** narrow-band UVB phototherapy

## Key facts

- **NCT ID:** NCT03715829
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-26
- **Primary completion:** 2021-02-05
- **Final completion:** 2021-02-05
- **Target enrollment:** 366 (ACTUAL)
- **Last updated:** 2022-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03715829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03715829, "A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03715829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*